Table 1

Baseline characteristics of axSpA patients treated with secukinumab with regard to the optimal report of a recommended composite index

CharacteristicsComposite index
Optimal report*Non-optimal reportWhole population
No197709906
Age (years: mean±SD, (N))46±13 (197)46±12 (709)46±12 (906)
Sex (n/N, (%) male)105/197 (53%)277/709 (39%)382/906 (42%)
HLA B27 (n/N, (% yes))32/189 (70%)395/636 (62%)527/825 (64%)
Smoking status
 Never (n/N; %)69/173; 40%257/542; 47%326/715; 46%
 Former (n/N; %)49/173; 28%109/542; 20%158/175: 22%
 Current (n/N; %)55/173; 32%76/542; 33%231/173; 32%
Body mass index
(m±SD (N))
27.2±5,3
(149)
26.9±5,6
(384)
27.0±5,5
(533)
Disease duration
(years: mean±SD; (N)
10±9
(188)
9±9
(619)
9±9
(807)
SIJ structural damage
(radiographic SpA); (n/N; (%))
152/197
(77%)
533/709
(75%)
685/906
(76%)
Past or present uveitis
(n/N, (%))
35/190
(18%)
96/669
(14%)
131/859
(15%)
Past or present IBD
(n/N, (%))
5/194
(3%)
17/684
(2.5%)
22/878
(2.5%)
Past or present psoriasis
(n/N, (%))
36/193
(19%)
158/684
(23%)
194/877
(22%)
Past or present peripheral arthritis
(n/N, (%))
59/183
(32%)
199/620
(32%)
258/803
(32%)
Past or present peripheral enthesitis
(n/N, (%))
90/181
(50%)
224/575
(39%)
314/756
(42%)
At least one objective
Sign of inflammation (n/N, (%))*
155/173
(90%)
462/542
(85%)
617/715,
(86%)
Secukinumab line of biological therapy
 First or second line (n/N, (%))53/196
(27%)
153/709
(22%)
206/906
(23%)
 ≥third line (n/N, (%))143/196
(73%)
550/709
(78%)
693/906
(77%)
  • *Objective sign of inflammation: either increased CRP or presence of inflammation at MRI of the sacroiliac joints/spine.

  • †Optimal report of a composite index : patients for whom a composite index (either (Bath Ankylosing Spondylitis Disease Acttivity Index (BASDAI) +CRP) or Ankylosing Sondylitis Disease Avtivity Score (ASDAS) has been optimally (at the time of the initiation of secukinumab and at least once during the first year of follow-up) has been reported.

  • axSpA, axial spondyloarthritis; CRP, C reactive protein; IBD, inflammatory bowel disease; SpA, spondyloarthritis.